Dihexa (developmental code name PNB-0408) is also known as:
- N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
- Hepatocyte growth factor (HGF) potentiator
- Neurotrophic peptide
- Neuroprotective peptide
- Regenerative peptide
- Alzheimer’s drug
- Nootropic drug
Dihexa is a small oligopeptide drug derived from angiotensin IV. It is thought to work by potentiating the activity of hepatocyte growth factor (HGF) at its receptor, c-Met. HGF is a potent neurotrophic factor that plays an important role in the development and maintenance of the nervous system. It also has neuroprotective and regenerative effects.
In animal studies, Dihexa has been shown to:
- Improve cognitive function
- Reduce amyloid beta plaques
- Promote the growth of new neurons in the hippocampus
- Protect neurons from damage
- Enhance nerve regeneration
- Improve blood flow to the brain
Based on these findings, Dihexa is being investigated for the treatment of Alzheimer’s disease and other neurological disorders.
Other potential uses of Dihexa
In addition to Alzheimer’s disease, Dihexa is also being investigated for the treatment of other neurological disorders, such as Parkinson’s disease, multiple sclerosis, and spinal cord injury. Dihexa is also being investigated for the treatment of cognitive impairment in cancer patients who are undergoing chemotherapy.
Safety and side effects of Dihexa
Dihexa has been shown to be safe and well-tolerated in clinical trials. However, some people may experience side effects such as nausea, vomiting, diarrhea, and headache. Dihexa is not recommended for pregnant or breastfeeding women.
Dihexa is a promising new drug for the treatment of Alzheimer’s disease and other neurological disorders. It is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease, and the results of these trials are eagerly awaited.
More research is needed to fully understand the potential benefits and risks of Dihexa. However, the existing evidence suggests that Dihexa is a promising new drug for the treatment of neurological disorders.
